LB Pharmaceuticals — Third Quarter 2026 Earnings Summary

LB Pharmaceuticals reported a net loss of $59.1 million for the third quarter of 2026, driven by increased research and development expenses related to its lead asset, LB-102. The company completed a $150 million private placement in July 2026, bringing its total cash, cash equivalents, and short-term investments to $403.8 million as of September 30, 2026. Leadership was strengthened with the appointments of Dr. Susan G. Kozauer as Chief Medical Officer and Joseph Miller as Chief Financial Officer. The company remains on track to report topline data from the pivotal Phase 3 NOVA-2 trial for schizophrenia in the first half of 2027.